Institutional Ownership
Kyverna Therapeutics Inc
CUSIP 501976104COMKYTXQ1 2026
13D / 13G Filings
10
Schedule 13D/13G on record
Beneficial Filers
8
Distinct reporting persons
Largest Stake
11.1%
Max % of class reported
Institutional Holders
107
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
10 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Northpond Ventures III, LP | 13G/A | 6.1% | 3.47M | SEC |
| 2 | Feb 17, 2026 | Bain Capital Life Sciences Opportunities III, LP | 13G/A | 5.4% | 3.11M | SEC |
| 3 | Feb 6, 2026 | Westlake Biopartners Fund I, L.P. ("Westlake Fund I") | 13G/A | 11.0% | 4.66M | SEC |
| 4 | Nov 17, 2025 | Gordonmd Global Investments LP | 13G | 7.0% | — | SEC |
| 5 | Nov 12, 2024 | Westlake Biopartners Fund I, L.P. | 13G | 8.8% | 3.79M | SEC |
| 6 | Oct 10, 2024 | Jpmorgan Chase & Co | 13G | 5.5% | 2.38M | SEC |
| 7 | May 3, 2024 | Vida Ventures, LLC | 13D | 11.1% | 4.78M | SEC |
| 8 | Feb 22, 2024 | Northpond Ventures III, LP | 13G | 1.0% | 450.0K | SEC |
| 9 | Feb 20, 2024 | Gilead Sciences, Inc. | 13G | 6.0% | 4.13M | SEC |
| 10 | Feb 14, 2024 | Bain Capital Life Sciences Opportunities III, LP | 13G | 7.4% | 3.16M | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Gordonmd Global Investments LP | 4.24M | $36.63M |
| 2 | Gilead Sciences, Inc. | 4.13M | $35.61M |
| 3 | Bain Capital Life Sciences Investors, LLC | 3.11M | $26.84M |
| 4 | Deerfield Management Company, L.P. | 2.00M | $17.26M |
| 5 | Aigh Capital Management LLC | 2.00M | $17.26M |
| 6 | Balyasny Asset Management L.P. | 1.13M | $9.71M |
| 7 | Millennium Management LLC | 1.01M | $8.68M |
| 8 | Insight Holdings Group, LLC | 989.1K | $8.54M |
| 9 | Morgan Stanley | 977.3K | $8.43M |
| 10 | Blackrock, Inc. | 877.1K | $7.57M |